Lonza Group AG/€LONN
1D1W1MYTD1Y5YMAX
Capital at risk
About Lonza Group AG
Lonza Group AG is a global company specializing in pharmaceutical, biotech, and nutrition sectors, headquartered in Basel, Switzerland. It provides integrated solutions for the creation of new drugs, ranging from active pharmaceutical ingredients (APIs) and drug formulation to drug delivery systems. The company serves a diverse clientele including pharmaceutical and biotech companies, offering contract development and manufacturing organization (CDMO) services. With operations in multiple countries, Lonza is strategically positioned to cater to global healthcare needs. Known for its extensive capabilities in cell and gene therapy, the organization leverages advanced technology platforms to support complex biopharmaceutical developments, enhancing its competitive edge in the industry.
- Ticker
- €LONN
- Sector
- Health
- Primary listing
- XGAT
- Employees
- 20,141
- Headquarters
- Basel, Switzerland
- Website
- www.lonza.com
Lonza Group AG Metrics
BasicAdvanced
€41B
-
-€1.67
0.84
€5.47
0.46%
Price and volume
Market cap
€41B
Beta
0.84
52-week high
€639.60
52-week low
€499.00
Average daily volume
114K
Dividend rate
€5.47
Financial strength
Current ratio
1.663
Quick ratio
0.588
Long term debt to equity
41.622
Total debt to equity
51.116
Interest coverage (TTM)
10.22%
Profitability
EBITDA (TTM)
2,540.737
Gross margin (TTM)
37.14%
Net profit margin (TTM)
-1.60%
Operating margin (TTM)
23.49%
Effective tax rate (TTM)
17.80%
Revenue per employee (TTM)
€361,440
Management effectiveness
Return on assets (TTM)
5.44%
Return on equity (TTM)
12.90%
Valuation
Price to revenue (TTM)
5.626
Price to book
4.78
Price to tangible book (TTM)
6.64
Price to free cash flow (TTM)
257.711
Free cash flow yield (TTM)
0.39%
Free cash flow per share (TTM)
2.282
Dividend yield (TTM)
0.93%
Forward dividend yield
0.46%
Growth
Revenue change (TTM)
25.91%
Earnings per share change (TTM)
-115.18%
3-year revenue growth (CAGR)
2.83%
10-year revenue growth (CAGR)
5.78%
3-year earnings per share growth (CAGR)
-53.12%
10-year earnings per share growth (CAGR)
-13.64%
3-year dividend per share growth (CAGR)
12.62%
10-year dividend per share growth (CAGR)
7.18%
Bulls say / Bears say
In H1 2026, Lonza delivered sales of CHF 3.4 billion, up 16% at constant exchange rates, with core EBITDA rising 27.4% to CHF 1.2 billion and margin expanding by 4.4 percentage points to 34.8% (Reuters)
Management upgraded the full-year 2026 core EBITDA margin outlook to 33–34%, reflecting strong operational execution and maturing growth projects, while maintaining sales growth guidance of 11–12% at constant exchange rates (Reuters)
Lonza announced plans to expand its payload-linker manufacturing capacity for highly potent active pharmaceutical ingredients at its Visp site, reinforcing its leading position in the rapidly growing antibody-drug conjugate market (FT)
Lonza’s shares fell around 4% on July 22, 2026, as investors reacted to the lack of upgraded sales guidance despite robust H1 results and concerns over a moderated second-half outlook (Reuters)
Utilization at Lonza’s Vacaville biologics site was only 30%, with management indicating sales will remain broadly flat through 2028, highlighting under-utilized capacity and deferred revenue potential (Reuters)
Management reiterated that growth and profitability would moderate in the second half of 2026 due to tougher year-ago comparisons and planned phasing of advanced synthesis activities, suggesting potential headwinds ahead (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2026.
Upcoming events
No upcoming events
Funds containing Lonza Group AG
AllEURGBPUSD
Fund name | Fund size | €LONN weighting |
|---|---|---|
Vanguard FTSE Developed Europe ex UK€VERX | €3.4B | 0.43% |
Vanguard FTSE Developed Europe ex UK£VERX | £2.9B | 0.43% |
Amundi STOXX Europe 600 ESG€C6E | €735M | 0.38% |
Amundi STOXX Europe 600€MEUD | €7.6B | 0.36% |
Xtrackers MSCI Europe£XMEU | £6.7B | 0.34% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.